RS68236B1 - Kokristali, njihove farmaceutske kompozicije i metode lečenja koje uključuju iste - Google Patents
Kokristali, njihove farmaceutske kompozicije i metode lečenja koje uključuju isteInfo
- Publication number
- RS68236B1 RS68236B1 RS20260702A RSP20260702A RS68236B1 RS 68236 B1 RS68236 B1 RS 68236B1 RS 20260702 A RS20260702 A RS 20260702A RS P20260702 A RSP20260702 A RS P20260702A RS 68236 B1 RS68236 B1 RS 68236B1
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- theta
- degrees
- pharmaceutical composition
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (16)
1. Patentni zahtevi
1. Kokristal koji sadrži jedinjenje formule (I)
i limunska kiselina.
2. Kokristal prema patentnom zahtevu 1, pri čemu je kokristal naznačen difraktogramom praha X-zraka, dobijenim u refleksivnom režimu, koji obuhvata:
(i) najmanje jednu poziciju pika, u stepenima 2-teta (± 0,2 stepena 2-teta), izabranu iz grupe koja se sastoji od 5.7, 8.4, 11.4, 15.8, 18.1, 19.2, 21.1, 22.5 i 23.0; i/ili:
(ii) najmanje dve pozicije pikova, u stepenima 2-teta (± 0,2 stepena 2-teta), izabrane iz grupe koja se sastoji od 5.7, 8.4, 11.4, 15.8, 18.1, 19.2, 21.1, 22.5 i 23.0; i/ili:
(iii) najmanje tri pozicije pikova, u stepenima 2-teta (± 0,2 stepena 2-teta), izabrane iz grupe koja se sastoji od 5.7, 8.4, 11.4, 15.8, 18.1, 19.2, 21.1, 22.5 i 23.0; i/ili:
(iv) najmanje četiri pozicije pikova, u stepenima 2-teta (± 0,2 stepena 2-teta), izabrane iz grupe koja se sastoji od 5.7, 8.4, 11.4, 15.8, 18.1, 19.2, 21.1, 22.5 i 23.0; i/ili:
(v) položaji pikova, u stepenima 2-teta (±0,2 stepena 2-teta), od 5.7 i 8.4, i najmanje tri polo žaja pikova izabrana iz grupe koja se sastoji od 11.4, 15.8, 18.1, 19.2, 21.1, 22.5 i 23.0.
3. Kokristal prema patentnom zahtevu 1 ili 2, pri čemu je kokristal naznačen diferencijalnom skenirajuć om kalorimetrijom termograma koji sadrži endotermni pik sa početnom temperaturom od 170.6 °C ( ±2.0 °C).
4. Kokristal prema bilo kojem od patentnih zahteva od 1 do 3, koji dodatno sadr ži vodu, opciono pri čemu su jedinjenje formule (I), limunska kiselina i voda prisutni u molarnom odnosu od 2:1:1; i/ili opciono pri čemu kokristal sadrži četiri molekula jedinjenja formule (I), dva molekula limunske kiseline i dva molekula vode po jediničnojć eliji.
5. Farmaceutska kompozicija koja sadrži terapeutski efikasnu količinu kokristala prema bilo kojem od patentnih zahteva od 1 do 4 i jedan ili više farmaceutskih ekscipijenata.
6. Kokristal prema bilo kojem od patentnih zahteva od 1 do 4 ili farmaceutska kompozicija prema patentnom zahtevu 5 za upotrebu u lečenju raka naznačeno prisustvom IDH1 ili IDH2 mutacije kod pacijenta kome je to potrebno.
7. Kokristal ili farmaceutska kompozicija prema patentnom zahtevu 6, pri čemu je rak naznačen prisustvom IDH1 mutacije; opciono pri čemu je IDH1 mutacija R132X mutacija.
8. Kokristal ili farmaceutska kompozicija prema patentnom zahtevu 7, pri čemu je IDH1 mutacija R132H ili R132C mutacija.
9. Kokristal ili farmaceutska kompozicija prema patentnom zahtevu 6, pri čemu je rak naznačen prisustvom IDH2 mutacije, opciono pri čemu je IDH2 mutacija R140X mutacija ili R172X mutacija.
10. Kokristal ili farmaceutska kompozicija prema patentnom zahtevu 9, pri čemu je IDH2 mutacija R140Q,
2
R140W ili R140L mutacija.
11. Kokristal ili farmaceutska kompozicija prema patentnom zahtevu 9, pri čemu je mutacija IDH2 R172K ili R172G mutacija.
12. Kokristal ili farmaceutska kompozicija prema bilo kojem od patentnih zahteva od 7 do 11, pri čemu mutacija IDH1 ili mutacija IDH2 dovodi do akumulacije R(-)-2-hidroksiglutarata kod pacijenta.
13. Kokristal ili farmaceutska kompozicija prema bilo kojem od patentnih zahteva od 6 do 12, pri čemu je rak izabran iz glioma, akutne mijeloidne leukemije, sarkoma, melanoma, nesitnoć elijskog raka plu ć a (NSCLC), holangiokarcinoma, hondrosarkoma, mijelodisplastičnih sindroma (MDS), mijeloproliferativne neoplazme (MPN), raka debelog creva i angioimunoblastnog ne-Hodžkinovog limfoma (NHL); opciono pri čemu je rak gliom.
14. Kokristal ili farmaceutska kompozicija prema patentnom zahtevu 13, pri čemu je gliom gliom niskog stepena ili sekundarni gliom visokog stepena, opciono pri čemu je gliom sekundarni gliom visokog stepena, i sekundarni gliom visokog stepena je glioblastom.
15. Kokristal ili farmaceutska kompozicija prema bilo kojem od patentnih zahteva od 6 do 14, pri čemu je rak refraktoran ili je u recidivu.
16. Kokristal ili farmaceutska kompozicija prema bilo kojem od patentnih zahteva od 6 do 14, pri čemu je rak novodijagnostikovan ili prethodno nije lečen.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580501P | 2017-11-02 | 2017-11-02 | |
| PCT/US2018/058930 WO2019090059A1 (en) | 2017-11-02 | 2018-11-02 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same |
| EP18812419.2A EP3704101B1 (en) | 2017-11-02 | 2018-11-02 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS68236B1 true RS68236B1 (sr) | 2026-07-31 |
Family
ID=64572453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20260702A RS68236B1 (sr) | 2017-11-02 | 2018-11-02 | Kokristali, njihove farmaceutske kompozicije i metode lečenja koje uključuju iste |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11345677B2 (sr) |
| EP (1) | EP3704101B1 (sr) |
| JP (3) | JP7335877B2 (sr) |
| KR (1) | KR102731624B1 (sr) |
| CN (2) | CN118359585A (sr) |
| AU (3) | AU2018360827B2 (sr) |
| CA (1) | CA3081535A1 (sr) |
| DK (1) | DK3704101T3 (sr) |
| EA (1) | EA202091112A1 (sr) |
| ES (1) | ES3075257T3 (sr) |
| FI (1) | FI3704101T3 (sr) |
| HR (1) | HRP20260783T1 (sr) |
| IL (2) | IL274123B2 (sr) |
| LT (1) | LT3704101T (sr) |
| MA (1) | MA50526B1 (sr) |
| MX (2) | MX2020004513A (sr) |
| PH (1) | PH12020550462A1 (sr) |
| PT (1) | PT3704101T (sr) |
| RS (1) | RS68236B1 (sr) |
| SG (1) | SG11202003612VA (sr) |
| SI (1) | SI3704101T1 (sr) |
| SM (1) | SMT202600262T1 (sr) |
| TW (2) | TWI796377B (sr) |
| UA (1) | UA127380C2 (sr) |
| WO (1) | WO2019090059A1 (sr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085832A1 (en) * | 2019-11-22 | 2020-03-19 | Agios Pharmaceuticals, Inc. | Deuterated analogs of an organic compound |
| TW202227446A (zh) | 2020-08-12 | 2022-07-16 | 美商施維雅製藥有限公司 | 有機化合物之固態形式 |
| US20230346789A1 (en) * | 2022-03-31 | 2023-11-02 | Msd International Gmbh | Methods of treating enhancing brain tumors using combination therapy |
| AR133332A1 (es) | 2023-07-25 | 2025-09-17 | Servier Lab | Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos |
| CN121843929A (zh) * | 2023-09-18 | 2026-04-10 | 贝达药业股份有限公司 | 突变型idh抑制剂化合物及其盐的固体形式 |
| EP4538262A1 (en) | 2023-10-12 | 2025-04-16 | Sandoz Ag | Cocrystals of vorasidenib |
| US20250257050A1 (en) | 2024-02-09 | 2025-08-14 | Les Laboratoires Servier | Process for the preparation of vorasidenib |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013010564B1 (pt) * | 2010-11-01 | 2021-09-21 | Celgene Car Llc | Compostos heterocíclicos e composições compreendendo os mesmos |
| SMT201800334T1 (it) | 2012-01-06 | 2018-09-13 | Agios Pharmaceuticals Inc | Composti terapeuticamente attivi e loro metodi di utilizzo |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
-
2018
- 2018-11-02 UA UAA202003279A patent/UA127380C2/uk unknown
- 2018-11-02 EA EA202091112A patent/EA202091112A1/ru unknown
- 2018-11-02 IL IL274123A patent/IL274123B2/en unknown
- 2018-11-02 CA CA3081535A patent/CA3081535A1/en active Pending
- 2018-11-02 US US16/760,520 patent/US11345677B2/en active Active
- 2018-11-02 ES ES18812419T patent/ES3075257T3/es active Active
- 2018-11-02 WO PCT/US2018/058930 patent/WO2019090059A1/en not_active Ceased
- 2018-11-02 MA MA50526A patent/MA50526B1/fr unknown
- 2018-11-02 AU AU2018360827A patent/AU2018360827B2/en active Active
- 2018-11-02 CN CN202410230044.7A patent/CN118359585A/zh active Pending
- 2018-11-02 JP JP2020524501A patent/JP7335877B2/ja active Active
- 2018-11-02 SG SG11202003612VA patent/SG11202003612VA/en unknown
- 2018-11-02 KR KR1020207015661A patent/KR102731624B1/ko active Active
- 2018-11-02 CN CN201880079771.0A patent/CN111527076B/zh active Active
- 2018-11-02 TW TW107139079A patent/TWI796377B/zh active
- 2018-11-02 IL IL305426A patent/IL305426B2/en unknown
- 2018-11-02 SI SI201831324T patent/SI3704101T1/sl unknown
- 2018-11-02 EP EP18812419.2A patent/EP3704101B1/en active Active
- 2018-11-02 FI FIEP18812419.2T patent/FI3704101T3/fi active
- 2018-11-02 DK DK18812419.2T patent/DK3704101T3/da active
- 2018-11-02 RS RS20260702A patent/RS68236B1/sr unknown
- 2018-11-02 LT LTEPPCT/US2018/058930T patent/LT3704101T/lt unknown
- 2018-11-02 PT PT188124192T patent/PT3704101T/pt unknown
- 2018-11-02 SM SM20260262T patent/SMT202600262T1/it unknown
- 2018-11-02 HR HRP20260783TT patent/HRP20260783T1/hr unknown
- 2018-11-02 MX MX2020004513A patent/MX2020004513A/es unknown
- 2018-11-02 TW TW112106677A patent/TWI839131B/zh active
-
2020
- 2020-04-22 PH PH12020550462A patent/PH12020550462A1/en unknown
- 2020-07-13 MX MX2022014792A patent/MX2022014792A/es unknown
-
2022
- 2022-04-19 US US17/723,666 patent/US11851417B2/en active Active
-
2023
- 2023-04-24 JP JP2023070786A patent/JP7499377B2/ja active Active
- 2023-11-08 US US18/504,859 patent/US12679820B2/en active Active
-
2024
- 2024-05-14 AU AU2024203186A patent/AU2024203186B2/en active Active
- 2024-06-03 JP JP2024090124A patent/JP7780576B2/ja active Active
-
2026
- 2026-07-13 AU AU2026205552A patent/AU2026205552A1/en active Pending